Dermatología en Costa Rica

Tuesday, June 21, 2016

Pruebas de Parche para identificar enfermedad inflamatoria intestinal.

Skin patch testing pinpoints dietary triggers of IBS 


AT DDW® 2016


VITALS
Key clinical point: Avoiding food allergens identified by skin patch testing significantly improved self-reported symptoms of irritable bowel syndrome.

Major finding: In all, 69% of patients reported at least moderate improvement after eliminating foods to which they reacted.

Data source: A single-arm proof-of-concept study of 57 patients with physician-diagnosed IBS.

Disclosures: Dr. Shin had no disclosures. Dr. Stierstorfer disclosed financial ties to IBS Centers for Advanced Food Allergy Testing.

SAN DIEGO – About 90% of patients reported improvement in symptoms of irritable bowel syndrome after avoiding type 4 food allergens identified by skin patch testing, according to an uncontrolled study.

Furthermore, 69% of patients reported at least moderate improvement after eliminating foods to which they reacted, said Dr. Michael Stierstorfer, a dermatologist at East Penn Dermatology in North Wales, Pa., who partnered with gastroenterologists at Temple University to conduct the study. "This raises questions about a possible overlap between IBS and allergic contact enteritis," the researchers stated in a poster presented at the annual Digestive Disease Week.

Dr. Michael Stierstorfer and Dr. Grace Shin
Amy Karon/Frontline Medical News
Dr. Michael Stierstorfer and Dr. Grace Shin

Irritable bowel syndrome is often treatment refractory and tends to elude conventional diagnostics. That was the case for Dr. Stierstorfer, who several years ago developed symptoms of IBS with constipation (IBS-C) that eventually affected him about half the time, he said in an interview. A hydrogen breath test, upper endoscopy, colonoscopy, abdominal/pelvic CT, and tests for gluten-sensitive enteropathy and parasites revealed no abnormalities except decreased small intestinal motility, he said.

But after "flaring badly" twice when he ate Indian food, he began to suspect a cause. "I stopped eating garlic and within a day, I was absolutely fine," Dr. Stierstorfer said. "The symptoms recurred only if I accidentally ate garlic again."

Studies had refuted links between IBS and type 1 hypersensitivity but had not explored the role of type 4 (delayed) hypersensitivity in the disorder, Dr. Stierstorfer discovered. "Dermatologists do patch testing all the time for patients with refractory eczema to search for type 4 allergic contact factors that might be causing their rash," he said. "I performed a patch test of garlic on myself to look for a type 4 allergy, and it was strongly positive. I thought I probably wasn't the only person walking around with symptoms that mimicked IBS but were really from a type 4 food allergy."

He tested that idea by skin patch testing 50 patients with IBS symptoms whom he recruited through his dermatology practice. In all, 30 (60%) patients reacted to at least one food allergen, of whom 14 (46%) reported symptomatic improvement after eliminating the suspected triggers from their diets. The findings appeared in the March 2013 Journal of the American Academy of Dermatology (68:377-84). 

Next, Dr. Stierstorfer partnered with Dr. Grace Shin, a 3rd-year gastroenterology fellow at Temple University, Philadelphia, and her colleagues. Together, they tested 57 patients with physician-diagnosed IBS with diarrhea (about 43% of patients), IBS with constipation (16%), mixed IBS (30%), or unsubtyped IBS (11%). Patients averaged 41 years of age (standard deviation, 15 years) and 77% were female. Each patient had between 118 and 122 individual allergen patches placed on his or her back. Two days later, the patches were removed and the skin evaluated for macular erythema consistent with a type 4 hypersensitivity reaction. The patients were checked again a day or 2 later to catch any highly delayed reactions. 

In all, 56 patients (98%) showed evidence of at least one hypersensitivity, and most reacted to between two and three allergens, Dr. Stierstorfer said. The most commonly identified triggers were cinnamon bark (35 patients; 61%) and sodium bisulfite (26 patients; 46%). At baseline, patients rated their abdominal pain or discomfort at an average of 6.7 on a 10-point severity scale (SD, 2.3 points). After 2-4 weeks of avoiding allergens to which they developed macular edema, they reported a mean 4.4-point improvement in their abdominal symptoms (SD, 2.7 points; P less than .001).

The patients also reported an average 5.8-point improvement on a 10-point scale of global IBS symptom severity (SD, 3.2 points; P less than .001). Overall, 91% of patients reported at least partial relief of abdominal symptoms, while 89% of patients reported at least partial relief of global symptoms, the investigators reported.

Based on these results, "food-related type 4 hypersensitivity reactions may contribute to the pathogenesis of IBS and IBS-like symptoms," Dr. Shin said in an interview. "The idea of allergic contact enteritis intrigued me, because it made me think that some patients diagnosed with IBS, especially IBS with diarrhea, might benefit from allergy testing when the standard approaches don't work." 

Another dietary intervention for IBS, the low-FODMAP diet, can help relieve symptoms, "but it's a hard diet to follow," Dr. Shin added. "Being able to focus on eliminating one or two things would be easier than eliminating multiple classes of foods that are so common to an American diet."

Next, the team is planning a controlled trial of the skin patch test. "There is still more validation work to do," said Dr. Stierstorfer. "But I think this shows that looking at something from a unique perspective – in this case, a dermatologic perspective for a GI problem – can result in a new approach, and potentially an advance in medicine."

Dr. Shin had no disclosures. Dr. Stierstorfer disclosed financial ties to IBS Centers for Advanced Food Allergy Testing.

Monday, June 20, 2016

Otro estudio contra el Chocolate con leche en el Acné...

Chocolate vs Jellybean Consumption

J Am Acad Dermatol; 2016 Jul; Delost, et al


JUNE 20, 2016

Consuming chocolate led to a greater increase in acne lesions vs eating jellybeans, according to a single-blind randomized crossover study involving 54 college students.

Participants were randomly assigned to receive a milk chocolate bar or 15 jellybeans (both containing the same glycemic load). Investigators blindly assessed acne changes after 48 hours via photographs. They also conducted a crossover analysis 4 weeks later to demonstrate adequate washout. 

The chocolate consumption group had a statistically significant increase in acne lesions (+4.8 lesions) vs the jellybean contingent (-0.7 lesions). 

The authors noted that chocolate flavonoid consumption modulates cytokine production, which likely accounts for their findings. 

Citation: Delost G, Delost M, Lloyd D. The impact of chocolate consumption on acne vulgaris in college students: A 

randomized crossover study. J Am Acad Dermatol. 2016;75(1):220-222. 

doi:http://dx.doi.org/10.1016/j.jaad.2016.02.1159

Saturday, June 18, 2016

Cáncer de Piel.

Friday, June 17, 2016

Medicamento para pestañas pequeñas o reducidas.

Dermatologic Surgery

Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis.

Carruthers, Jean MD; Beer, Kenneth MD, FAAD; Carruthers, Alastair MD; Coleman, William P. III MD; Draelos, Zoe Diana MD; Jones, Derek MD; Goldman, Mitchel P. MD; Pucci, Michael L. PhD; VanDenburgh, Amanda PhD; Weng, Emily ScD, MBA; Whitcup, Scott M. MD

Dermatologic Surgery
Post Author Corrections: April 28, 2016


BACKGROUND: Eyebrow loss may have substantial negative functional and social consequences.

OBJECTIVE: Evaluate the safety and efficacy of bimatoprost 0.03% in subjects with eyebrow hypotrichosis.

METHODS: This multicenter, double-masked study randomized adult females or males with eyebrow hypotrichosis to receive bimatoprost 0.03% twice (BID) or once daily (QD) or vehicle BID for 7 months. Primary endpoint was overall eyebrow fullness at Month 7. Secondary endpoints included eyebrow fullness (mm2), darkness (intensity units), and subject satisfaction with treatment. Safety was also assessed.

RESULTS: At Month 7, the proportion of subjects with improvement was significantly higher in bimatoprost groups versus vehicle (both, p < .001). Improvements occurred in both bimatoprost groups versus vehicle after Month 1 and continued through follow-up; eyebrow fullness and darkness improved as early as Months 2 and 1, respectively (both, p < .001). Greater satisfaction was reported with bimatoprost versus vehicle at Month 2 and all subsequent time points. Overall, 38.1%, 42.4%, and 35.5% of subjects in the bimatoprost BID, QD, and vehicle groups, respectively, experienced >=1 treatment-emergent adverse event (TEAE). Most frequent TEAEs were similar across groups. No skin or iris hyperpigmentation or conjunctival hyperemia occurred.

CONCLUSION: Bimatoprost 0.03% BID and QD is safe, well tolerated, and effective for eyebrow hypotrichosis.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

(C) 2016 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Thursday, June 16, 2016

Tratamientos tópicos también son efectivos en carcinoma basocelular.

Topical Skin Creams Effective to Treat Superficial Basal Cell Carcinoma

June 2, 2016

PHILADELPHIA -- June 2, 2016 -- A 3-year randomised controlled clinical trial has found that 2 topical creams are effective for most patients with primary, low-risk superficial basal cell carcinoma (BCC), comparing favourably with photodynamic therapy (PDT), according to a study published in the Journal of Investigative Dermatology.

Topical treatments are available for superficial BCC, but there has been a lack of long-term follow-up data to guide treatment decisions. While most types of BCC require surgery, superficial BCC can be treated topically with noninvasive treatments such as PDT, imiquimod cream, fluorouracil cream, cryosurgery or electrodessication and curettage.

The current study compared 3 noninvasive treatments that included imiquimod and fluorouracil cream.

"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams," said lead investigator Marieke Roozeboom, MD, Department of Dermatology, Maastricht University Medical Center, Maastricht, the Netherlands. "Throughout the last 2 decades there has been a growing interest in these non-surgical therapies, which offer the possibility of avoiding surgery and reducing demands on busy medical practices."

A total of 601 patients with a superficial BCC participated in the study. Of the patients, 202 were treated with methylaminolevulinate photodynamic therapy (MAL-PDT), 198 with imiquimod cream, and 201 with fluorouracil cream. The 3 study groups had a similar distribution of baseline characteristics, with the exception of tumour size.

Around 80% of patients with superficial BCC were tumour-free after imiquimod treatment after 3 years. The clearance rate was 68% for patients treated with fluorouracil and 58% for individuals receiving PDT.

"Based on our findings, both imiquimod and fluorouracil are effective noninvasive treatments in most primary, low-risk superficial BCC, but the data provide no definite evidence for superiority of imiquimod to fluorouracil," said Dr. Roozeboom. "Both creams have an equal cosmetic outcome and risk of local adverse events. Fluorouracil has the advantage of being less expensive than imiquimod. However, between 1- and 3-year follow-up, more recurrences were diagnosed in the fluorouracil group compared with the imiquimod group."

"When choosing a treatment for an individual patient with a superficial BCC, other factors like age, compliance, and patient preferences should always be taken into account," he added. "For example, we have found that in superficial BCC on the lower extremities in older patients, PDT should be prescribed rather than imiquimod. Our evidence indicates that a personalized treatment approach is necessary."

SOURCE: Elsevier

Wednesday, June 15, 2016

Medicamentos para disfunción erectil, no incrementan el riesgo de melanoma, un alivio para los pacientes.


Three Widely Used Erectile Dysfunction Medications Not Likely To Increase Risk Of Melanoma, Research Suggests.

HealthDay (6/14, Preidt) reports that research suggests "three widely used erectile dysfunction drugs – Cialis [tadalafil], Levitra [vardenafil] and Viagra [sildenafil] – aren't likely to boost the risk of melanoma skin cancer." The findings were published in PLoS Medicine. HealthDay points out that there had been "concern" because "laboratory tests" had "suggested that lower levels of an enzyme that's inhibited by certain erectile dysfunction" medications may "increase the growth of melanoma cells," although "studies examining melanoma risk among men who take these drugs have had conflicting results."


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Tuesday, June 14, 2016

Repelentes: DEET 20 a 50%, picardina 20% y aceite de eucalipto limón 30%, así como IR3535...



Mosquito Repellents: Everything You Need to Tell Your Patients

Brenda Goodman

June 03, 2016

Thwack. They're baaaack. Yep, it's mosquito season again.

It's not just about itchy bumps, either -- mosquito bites can make you sick, especially if you're traveling. Think Zika, chikungunya, West Nile, dengue, or even malaria or yellow fever if you're going to some parts of Africa.

That means you need some insect repellent -- but surprisingly, lots of people don't use it. An April 2016 survey done by market research firm TNS Global found that only about half of Americans (49%) follow the CDC's recommendation to use a mosquito repellent.

Zika poses a particular danger to pregnant women, since it causes birth defects. As it creeps northward from South America and the Caribbean, health officials' mission is to get the message out loud and clear: Mosquito repellents are safe, and you should use them.

And there are more choices than ever.

The product that's right for you will depend on why you need it. Are you pregnant or traveling to an area with a lot of mosquito-borne disease? Are you fishing or camping and handling lots of gear? Are you applying it to a young child's skin? All those things should factor into your buying decision.

We reached out to mosquito experts for advice on choosing and using these products. Here are their rules for making mosquito repellents work for you.

What's the best active ingredient?

According to the CDC and EPA, there are four ingredients to look for: DEET, picaridin, oil of lemon eucalyptus or PMD, and IR3535.

DEET is the granddaddy of bug stoppers. It was developed by the U.S. military in 1946, and it's the most widely used and studied active ingredient out there. It's long gotten a bad rap as a scary chemical, but experts say that reputation isn't justified, even for pregnant women. Extremely high doses have, on rare occasions, caused nervous system problems like seizures, tremors, and slurred speech, though, so it's still worth handling with care.

It's found in products like Off! Deep Woods spray, Sawyer's Ultra 30 Insect Repellent lotion, and 3M's Ultrathon Insect Repellent lotions and sprays.

While no repellent has been studied extensively in pregnancy, DEET at least has a little data backing its safety. A study of nearly 900 pregnant women in Thailand, which followed moms and babies for a full year after birth, found no harmful effects of DEET used on the skin during the second and third trimesters. Animal studies have also failed to find any ill effects of DEET to a fetus when applied at any stage of pregnancy.

No other active ingredient has been studied during pregnancy. For that reason, some doctors say DEET should be your go-to if you're expecting. The EPA, on the other hand, puts no restrictions on the use of any repellents during pregnancy.

But DEET has its drawbacks, too. It can be heavy and feel oily on the skin. And it has a pungent odor. It also melts plastic, which is bad news for fishing and camping gear, synthetic fabrics like spandex, or even a nice pair of sunglasses. So, if a heightened sense of smell is keeping you from putting it on, or you don't want it to ruin your gear or clothes, choose a different option.

Picaridin is a chemical cousin of piperine, a chemical made by black pepper plants. It's been widely used in Europe and Australia, but has only been available in the U.S. since 2005. It can be found in sprays, lotions, and wipes, including Sawyer's Premium Picaridin Insect Repellent lotions and sprays, Avon's Skin So Soft Bug Guard Plus Picaridin Pump, and Cutter Advanced Insect Repellent Fragrance Free Wipes. In recent tests, Consumer Reports gave two picaridin products top marks for repelling the species of mosquitoes that carries the Zika virus for 8 full hours.

The chemical PMD (for para-menthane-3,8-diol) is also sometimes labeled as oil of lemon eucalyptus. It's a chemical copy of a pungent oil made by the lemon eucalyptus tree. It can be found in Cutter Lemon Eucalyptus spray and Repel Lemon Eucalyptus. In Consumer Reports' tests, the Repel product, which contains 30% PMD, kept mosquitos away for 7 hours.

IR3535 has been used in Europe for 20 years, but was only registered in the U.S. in 1999. It's a close chemical cousin to the amino acid B-alanine. Like DEET, it can harm plastics and synthetic fabrics. Manufacturers also warn that it can mar painted surfaces, including a recent manicure. No IR3535 products made Consumer Reports' list of recommended repellents.

How strong should your repellent be?

Depends on how long you need it to last.

The first thing you'll notice when you start checking labels is that insect repellents come in different strengths. You can find concentrations of DEET, for example, ranging from 4% up to 100%.

Do you really need a product that's pure DEET? Experts say no, but you want to avoid the lowest concentrations, too. Here's why.

After being sprayed or rubbed on the skin, the active ingredients in repellents begin to evaporate, creating a chemical cloud -- or "vapor barrier" -- that hovers around you and keeps mosquitoes at bay.

It takes a concentration of about 20% DEET to create a strong-enough barrier, especially in an area that has a lot of mosquito-borne diseases. Higher concentrations help the barrier last longer. But that protection maxes out around 50%. Any more than that exposes you to more chemical, but doesn't provide more protection.

A product with 20% to 50% DEET should give you 6 to 13 hours of protection, depending on weather conditions.

Repellents with 30% PMD or oil of lemon eucalyptus keep mosquitoes away for 4 to 6 hours.

Products with at least 20% picaridin last for about 6 hours.

And repellents with at least 20% IR3535 work for 7 to 10 hours, but they don't work as well against the species of mosquito that carries malaria. So, pick another kind of active ingredient if you're going to an area where that's a problem.

Time-released lotions use a lower concentration of active ingredient, but they can protect you longer.

What about natural or homemade repellents?

When fighting mosquitoes, "natural" is not the way to go. In recent tests, Consumer Reports found that four repellents made with essential oils of citronella, clove, lemongrass, or rosemary failed to keep the bloodsuckers at bay for even an hour. (PMD, or oil of lemon eucalyptus, is not considered "natural," since it's a chemical copy of the oil.)

Other home remedies to be wary of include Listerine, which may give you minty fresh breath but doesn't block mosquitoes if you rub it on your skin, and garlic pills or B vitamins, since there's no evidence they offer any protection.

Spray vs. lotion

Sprays work faster, says Joseph Conlon, a technical advisor for the American Mosquito Control Association.

"Lotions will take approximately 20 minutes to allow the concentration of repellent layer above the skin to exert its effect," he says.

But lotions can have other advantages. Some have time-released ingredients so that a lower concentration of active ingredient can offer longer protection, which reduces a person's chemical exposure, too.

Guarding against the sun and bugs at the same time?

A few studies have shown that using a bug repellent with a sunscreen can make both products less effective. But sometimes you need both. So, what do you do?

The CDC suggests starting with sunscreen, then putting mosquito repellent over it. Keep in mind that you may need to reapply the sunscreen more often than you normally would and that your bug spray may wear off more quickly than expected.

The CDC says it's not a good idea to use products that combine a sunscreen with a repellent, since sunscreens need to be reapplied more often than repellents. Using a combination product frequently could result in higher-than-needed doses of repellent chemicals.

Do I really need a new bottle?

Maybe not. But before you fish out the rusty can you keep stashed with the camping gear, keep in mind that most products are optimally effective for 3 years after you buy them, according to S.C. Johnson, the company that makes OFF. And that's only if they haven't been exposed to extreme heat or cold. Most products will continue to work after that, but they may not last as long.

Is it safe to put insect repellents on kids?

Yes. Products with DEET can be used on babies older than 8 weeks of age. Picaridin is considered safe for kids over the age of 2, and products with PMD/oil of lemon eucalyptus are considered safe for kids older than 3. There's no safety data on the use of IR3535 for kids.

Be sure to read the directions before applying. One survey found as many of a third of parents apply insect repellents incorrectly. A few "don'ts":

· Don't apply to kids' hands, since they often put them in their mouths.

· Don't apply before kids get dressed. Insect repellents should only be used on exposed skin and clothing. It doesn't do any good to use it under clothing.

· Don't forget to wash off at the end of the day with soap and water. It's not a good idea to sleep with repellents on, since this increases the absorption of the chemicals.

Why didn't my repellent work?

According to experts, the No. 1 reason repellents don't work is because they were put on incorrectly, so read the directions and apply thoroughly.

"Most repellents have pretty clear instructions on the label about how to apply them, but people never, ever read the label," says Jonathan Day, PhD, a professor at the University of Florida's Medical Entomology Laboratory in Vero Beach, FL.

If you did everything correctly and you still came home covered in bites, there might be another explanation.

There's emerging science to suggest that mosquitoes can become resistant to DEET and perhaps other insect repellents, too.

James Logan, PhD, is the director of ArcTec (Arthropod Control Product Test Centre) at the London School of Hygiene and Tropical Medicine in the U.K.

He applied DEET to a human arm and then let a cage full of mosquitoes approach to feed on it. Most mosquitoes stayed away, but 13% of the females weren't repelled by the DEET. He captured and bred those mosquitoes and then repeated the experiment with their daughters. In the next generation, about half of the mosquitoes weren't repelled by DEET.

In another set of experiments, he unleashed the bugs to a human arm covered in DEET. Then he waited 3 hours and exposed those same mosquitoes to a DEET-covered arm again. On the second try, more than twice as many mosquitoes landed and fed as they had the first time, suggesting that they had somehow gotten used to it.

"They can become resistant through genetics and behaviorally as well," Logan says.

He's quick to point out that his experiments were done in a carefully controlled lab, and not in a house or backyard. Researchers don't know if mosquitoes in the wild are becoming resistant to DEET.

"What we don't know is whether this is occurring in the field. Nobody has ever looked at it," he says. He's working to answer the question now.

It's possible, he says, that people might need to use two different kinds of repellents at the same time to boost their effectiveness.

"The point is that repellents should be used. They should be recommended. There should be no scare mongering about the fact that DEET may fail. That is not necessarily the case. As scientists, we need to be monitoring the situation and staying one step ahead of the game, and not making assumptions that it will be OK. Mosquitoes have a very good way of being one step ahead of us and finding a way 'round the tools we have to control them."

SOURCES:

Amy Stead, spokesperson, Sawyer Products, Bellevue, WA.

James Logan, PhD, director, ArcTec, The London School of Hygiene and Tropical Medicine, London, U.K.

Joseph Conlon, technical advisor, The American Mosquito Control Association, Mount Laurel, N.J.

Jonathan Day, PhD, professor, The Florida's Medical Entomology Laboratory, The University of Florida, Vero Beach, FL.

Alpern. Medical Clinics of North America, 2016.

Stanczyk, N., BMJ, Feb. 19, 2015.

CDC: "Insect Repellent Use and Safety."

 

Thursday, June 09, 2016

Cicatrices de acné son muy importantes para los pacientes, pierden confianza en sí mismos.

San Diego, CA (June 7, 2016)Suneva Medical, Inc., a privately-held aesthetics company, has revealed the results of a new acne scar survey in recognition of June's Acne Awareness Month. The survey found that the overwhelming majority of consumers believe acne and acne scars have a negative impact on a person's confidence. Also, people with acne and acne scars normally withdraw themselves from social settings and avoid putting photos online without heavy editing or filters.1 The statistics further pinpoint the unfortunate realities of those who suffer from acne and its associated scarring, while underscoring the need for treatment options that address these widespread skin conditions.

Key findings from the survey include:

  • 99 percent of survey respondents believe someone has more confidence when their acne and acne scars are cleared up
  • When it comes to skin issues, consumers believe acne scars are worse than having acne, eczema or rosacea
  • Nearly half of adults still suffer from acne or acne scars and have not outgrown these skin conditions
  • 48 percent withdraw from social outings and parties with friends because of their acne scars or facial blemishes
  • 61 percent would wear less makeup if they were able to effectively treat acne scars and minimize their scarring's appearance
  • 49 percent of people with acne scars or blemishes prevent themselves from putting photos online without heavy editing or filters
  • 54 percent do not feel confident on a date because of their acne scars or facial blemishes
  • 81 percent of respondents would select clear skin over keeping their fashion on trend, a nail manicure maintained, or maintaining a hairstyle that is rivaled by celebrities

"Acne scarring is one of the most common skin issues I see at my practice and the condition is more than skin deep. The millions of people who suffer from acne scars carry an emotional burden that brings on feelings of depression and low self-esteem," said Dr. Ava Shamban, board-certified dermatologist and one of the country's leading authorities on skin. "These individuals should not lose hope

Cremas topicas para carcinoma basocelular superficial.


Topical Skin Creams Effective to Treat Superficial Basal Cell Carcinoma

Junio 2, 2016

PHILADELPHIA -- June 2, 2016 -- A 3-year randomised controlled clinical trial has found that 2 topical creams are effective for most patients with primary, low-risk superficial basal cell carcinoma (BCC), comparing favourably with photodynamic therapy (PDT), according to a study published in the Journal of Investigative Dermatology.

Topical treatments are available for superficial BCC, but there has been a lack of long-term follow-up data to guide treatment decisions. While most types of BCC require surgery, superficial BCC can be treated topically with noninvasive treatments such as PDT, imiquimod cream, fluorouracil cream, cryosurgery or electrodessication and curettage.

The current study compared 3 noninvasive treatments that included imiquimod and fluorouracil cream.

"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams," said lead investigator Marieke Roozeboom, MD, Department of Dermatology, Maastricht University Medical Center, Maastricht, the Netherlands. "Throughout the last 2 decades there has been a growing interest in these non-surgical therapies, which offer the possibility of avoiding surgery and reducing demands on busy medical practices."

A total of 601 patients with a superficial BCC participated in the study. Of the patients, 202 were treated with methylaminolevulinate photodynamic therapy (MAL-PDT), 198 with imiquimod cream, and 201 with fluorouracil cream. The 3 study groups had a similar distribution of baseline characteristics, with the exception of tumour size.

Around 80% of patients with superficial BCC were tumour-free after imiquimod treatment after 3 years. The clearance rate was 68% for patients treated with fluorouracil and 58% for individuals receiving PDT.

"Based on our findings, both imiquimod and fluorouracil are effective noninvasive treatments in most primary, low-risk superficial BCC, but the data provide no definite evidence for superiority of imiquimod to fluorouracil," said Dr. Roozeboom. "Both creams have an equal cosmetic outcome and risk of local adverse events. Fluorouracil has the advantage of being less expensive than imiquimod. However, between 1- and 3-year follow-up, more recurrences were diagnosed in the fluorouracil group compared with the imiquimod group."

"When choosing a treatment for an individual patient with a superficial BCC, other factors like age, compliance, and patient preferences should always be taken into account," he added. "For example, we have found that in superficial BCC on the lower extremities in older patients, PDT should be prescribed rather than imiquimod. Our evidence indicates that a personalized treatment approach is necessary."

SOURCE: Elsevier


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Tuesday, June 07, 2016

Lacteos y acné, estudio dice que no hay gran diferencia.

Yo les hablo a los pacientes sobre mi idea de que sí hay relación entre la dieta y el su acné, en algunos pacientes, y si ellos establecen que sí hay un nexo, que difieran de ingerir estos alimentos.
Éste artículo establece que no hay una correlación directa, pero no niega la asociación.

Journal of the American Academy of Dermatology
Consumption of Dairy in Teenagers With and Without Acne
J Am Acad Dermatol 2016 May 27;[EPub Ahead of Print], CL LaRosa, KA Quach, K Koons, AR Kunselman, J Zhu, DM Thiboutot, AL Zaenglein 

BACKGROUND

Recent literature has implicated dairy as having a potential acne-inducing effect.

OBJECTIVES

The aim of this study was to investigate the link between dairy consumption and acne in teenagers. We tested the hypothesis that teenagers with facial acne consume more dairy than those without acne.

METHODS

A case-control study was conducted among 225 participants, ages 14 to 19 years, with either moderate acne or no acne. Moderate acne was determined by a dermatologist using the Global Acne Assessment Scale. Participants who met inclusion criteria then completed up to three 24-hour diet recall interviews using the Nutrition Data System for Research software and food and nutrient intake were compared between groups.

RESULTS

The amount of low-fat/skim milk consumed by participants with acne with significantly higher (P = .01) than those with no acne. No significant difference was found among total dairy intake, saturated fat or trans-fat, or glycemic load. No significant difference was found for total energy intake or body mass index.

LIMITATIONS

Limitations include self-report of diet and portion size, and association does not determine causation.

CONCLUSIONS

Consumption of low-fat/skim milk, but not full-fat milk, was positively associated with acne.

TAKE-HOME MESSAGE


Monday, June 06, 2016

Signos cancer de piel...

Persistente, facilmente irritable, en crecimiento o recurrente.

Friday, June 03, 2016

Los corticoides topicos siguen siendo los tratamientos con mayor nivel de evidencia en el manejo de la Dermatitis atopica.

Las opciones terapeuticas para el tratamiento de los pacientes con dermatitis atópica no son muchas, pero el miedo a los corticoides ocurre por nuestra falta de información sobre el uso correcto de los mismos a los padres de pacientes y pacientes, pero los inhibidorss topicos de calcineurina demuestran gran eficacia tambien.

Background

Calcineurin inhibitors are alternatives to corticosteroid for treatment of atopic dermatitis.

Objectives

We sought to compare the beneficial effects and adverse events associated with these therapies in treating patients with atopic dermatitis.

Methods

Four databases were searched for randomized clinical trials comparing topical calcineurin inhibitors versus corticosteroids in children and adults. Methodological quality was evaluated to assess bias risk. Clinical outcome and costs were compared.

Results

Twelve independent randomized clinical trials comparing calcineurin inhibitors (n = 3492) versus corticosteroids (n = 3462) were identified. Calcineurin inhibitors and corticosteroids had similar rates of improvement of dermatitis (81% vs 71%; risk ratio [RR] 1.18; 95% confidence interval [CI] 1.04-1.34; P = .01) and treatment success (72% vs 68%; RR 1.15; 95% CI 1.00-1.31; P = .04). Calcineurin inhibitors were associated with higher costs and had more adverse events (74% vs 64%; RR 1.28; 95% CI 1.05-1.58; P = .02) including a higher rate of skin burning (30% vs 9%; RR 3.27; 95% CI 2.48-4.31; P < .00001) and pruritus (12% vs 8%; RR 1.49; 95% CI 1.24-1.79; P < .00001). There were no differences in atrophy, skin infections, or adverse events that were serious or required discontinuation of therapy.

Limitations

Only a small number of trials reported costs.

Conclusion

Calcineurin inhibitors and corticosteroids have similar efficacy. Calcineurin inhibitors are associated with higher costs and have more adverse events, such as skin burning and pruritus. These results provide level-1a support for the use of corticosteroids as the therapy of choice for atopic dermatitis.

Key words:

atopic dermatitis, calcineurin inhibitors, corticosteroids, meta-analysis, randomized controlled trial, systematic review

Abbreviations used:

CI (confidence interval), FDA (Food and Drug Administration), RCT (randomized clinical trial), RR (risk ratio)

Funding sources: None.

Conflicts of interest: None declared.


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Agua dura... Mayor prevalencia de Dermatitis Atopica...

Estudio observacional, encuentra que en zonas donde hay agua dura, los niños presentan más dermatitis atópica. No es un estudio de causa y efecto, es observacional y requiere otros estudios, pero sí es interesante, comentan los autores.

Background

Domestic water hardness and chlorine have been suggested as important risk factors for atopic dermatitis (AD).

Objective

We sought to examine the link between domestic water calcium carbonate (CaCO3) and chlorine concentrations, skin barrier dysfunction (increased transepidermal water loss), and AD in infancy.

Methods

We recruited 1303 three-month-old infants from the general population and gathered data on domestic water CaCO3 (in milligrams per liter) and chlorine (Cl2; in milligrams per liter) concentrations from local water suppliers. At enrollment, infants were examined for AD and screened for filaggrin (FLG) skin barrier gene mutation status. Transepidermal water loss was measured on unaffected forearm skin.

Results

CaCO3 and chlorine levels were strongly correlated. A hybrid variable of greater than and less than median levels of CaCO3 and total chlorine was constructed: a baseline group of low CaCO3/low total chlorine (CaL/ClL), high CaCO3/low total chlorine (CaH/ClL), low CaCO3/high total chlorine (CaL/ClH) and high CaCO3/high total chlorine (CaH/ClH). Visible AD was more common in all 3 groups versus the baseline group: adjusted odds ratio (AOR) of 1.87 (95% CI, 1.25-2.80; P = .002) for the CaH/ClL group, AOR of 1.46 (95% CI, 0.97-2.21; P = .07) for the CaL/ClH, and AOR of 1.61 (95% CI, 1.09-2.38; P = .02) for the CaH/ClH group. The effect estimates were greater in children carrying FLG mutations, but formal interaction testing between water quality groups and filaggrin status was not statistically significant.

Conclusions

High domestic water CaCO3 levels are associated with an increased risk of AD in infancy. The influence of increased total chlorine levels remains uncertain. An intervention trial is required to see whether installation of a domestic device to decrease CaCO3levels around the time of birth can reduce this risk.


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.